1. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.
- Author
-
Fu, Jiang-Tao, Liu, Jian, Wu, Wen-Bin, Chen, Yi-Ting, Lu, Guo-Dong, Cao, Qi, Meng, Hong-Bo, Tong, Jie, Zhu, Jia-Hui, Wang, Xu-Jie, Liu, Yi, Zhuang, Chunlin, Sheng, Chunquan, Shen, Fu-Ming, Liu, Xingguang, Wang, Hua, Yu, Yongsheng, Zhang, Yuefan, Liang, Hai-Yan, and Zhang, Jia-Bao
- Subjects
- *
NON-alcoholic fatty liver disease , *MYELOID cells , *KUPFFER cells , *FATTY liver , *GENE expression - Abstract
The precise pathomechanisms underlying the development of non-alcoholic steatohepatitis (NASH, also known as metabolic dysfunction-associated steatohepatitis [MASH]) remain incompletely understood. In this study, we investigated the potential role of EF-hand domain family member D2 (EFHD2), a novel molecule specific to immune cells, in the pathogenesis of NASH. Hepatic EFHD2 expression was characterized in patients with NASH and two diet-induced NASH mouse models. Single-cell RNA sequencing (scRNA-seq) and double-immunohistochemistry were employed to explore EFHD2 expression patterns in NASH livers. The effects of global and myeloid-specific EFHD2 deletion on NASH and NASH-related hepatocellular carcinoma were assessed. Molecular mechanisms underlying EFHD2 function were investigated, while chemical and genetic investigations were performed to assess its potential as a therapeutic target. EFHD2 expression was significantly elevated in hepatic macrophages/monocytes in both patients with NASH and mice. Deletion of EFHD2, either globally or specifically in myeloid cells, improved hepatic steatosis, reduced immune cell infiltration, inhibited lipid peroxidation-induced ferroptosis, and attenuated fibrosis in NASH. Additionally, it hindered the development of NASH-related hepatocellular carcinoma. Specifically, deletion of myeloid EFHD2 prevented the replacement of TIM4+ resident Kupffer cells by infiltrated monocytes and reversed the decreases in patrolling monocytes and CD4+/CD8+ T cell ratio in NASH. Mechanistically, our investigation revealed that EFHD2 in myeloid cells interacts with cytosolic YWHAZ (14-3-3ζ), facilitating the translocation of IFNγR2 (interferon-γ receptor-2) onto the plasma membrane. This interaction mediates interferon-γ signaling, which triggers immune and inflammatory responses in macrophages during NASH. Finally, a novel stapled α-helical peptide targeting EFHD2 was shown to be effective in protecting against NASH pathology in mice. Our study reveals a pivotal immunomodulatory and inflammatory role of EFHD2 in NASH, underscoring EFHD2 as a promising druggable target for NASH treatment. Non-alcoholic steatohepatitis (NASH) represents an advanced stage of non-alcoholic fatty liver disease (NAFLD); however, not all patients with NAFLD progress to NASH. A key challenge is identifying the factors that trigger inflammation, which propels the transition from simple fatty liver to NASH. Our research pinpointed EFHD2 as a pivotal driver of NASH, orchestrating the over-activation of interferon-γ signaling within the liver during NASH progression. A stapled peptide designed to target EFHD2 exhibited therapeutic promise in NASH mice. These findings support the potential of EFHD2 as a therapeutic target in NASH. [Display omitted] • EFHD2 exhibits specific expression in hepatic macrophages/monocytes and is induced in NASH liver. • Global or myeloid cell-specific deletion of EFHD2 improves NASH and hinders NASH-HCC progression. • EFHD2 regulates the replacement of resident Kupffer cells by infiltrating monocytes during NASH. • EFHD2 interacts with YWHAZ, promoting translocation of IFNγR2 to the plasma membrane and, in turn, mediating IFNγ signaling. • A novel stapled peptide designed to target EFHD2 demonstrates protective effects against NASH in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF